Table 2.
Risk of breast cancer in relation to the EDA ratio1
| Case (n=191) | Control (n=194) | OR (95% CI) | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Overall (N=385) | |||||
| EDA:EMC ratio | |||||
| Quartile 1 | 44 | 23.0 | 48 | 24.7 | 1.00 (Ref) |
| Quartile 2 | 54 | 28.3 | 49 | 25.3 | 1.57 (0.76,3.22) |
| Quartile 3 | 62 | 32.5 | 48 | 24.7 | 1.67 (0.82,3.41) |
| Quartile 4 | 31 | 16.2 | 49 | 25.3 | 0.95 (0.42,2.15) |
| Mean | SD | Mean | SD | ||
| EDA:EMC ratio, continuous2 | 2.3 | 0.8 | 2.4 | 1.1 | 0.93 (0.71,1.23) |
| EDA, continuous2,3 | 7.8 | 0.7 | 7.8 | 0.8 | 1.05 (0.74,1.49) |
| EMC, continuous2,3 | 13.4 | 0.6 | 13.3 | 0.6 | 1.26 (0.80,2.00) |
|
4-catechol estrogen pathway EDA:EMC ratio |
N | % | N | % | |
| Quartile 1 | 36 | 18.9 | 49 | 25.3 | 1.00 (Ref) |
| Quartile 2 | 58 | 30.4 | 48 | 24.7 | 1.95 (0.96,3.99) |
| Quartile 3 | 47 | 24.6 | 48 | 24.7 | 1.16 (0.55,2.47) |
| Quartile 4 | 50 | 26.2 | 49 | 25.3 | 1.68 (0.80,3.56) |
| Mean | SD | Mean | SD | ||
| 4-EDA:EMC ratio, continuous2 | 1.2 | 1.0 | 1.2 | 1.3 | 1.04 (0.82,1.30) |
|
2-catechol estrogen pathway EDA:EMC ratio |
N | % | N | % | |
| Quartile 1 | 48 | 25.1 | 49 | 25.3 | 1.00 (Ref) |
| Quartile 2 | 63 | 33.0 | 48 | 24.7 | 1.92 (0.95,3.88) |
| Quartile 3 | 49 | 25.7 | 49 | 25.3 | 1.13 (0.55,2.34) |
| Quartile 4 | 31 | 16.2 | 48 | 24.7 | 0.81 (0.37,1.78) |
| Mean | SD | Mean | SD | ||
| 2-EDA:EMC ratio, continuous2 | 1.6 | 0.9 | 1.8 | 1.0 | 0.84 (0.65,1.10) |
| Among ER+ breast cancer and matched controls (N=296) | |||||
| EDA:EMC ratio | |||||
| Quartile 1 | 34 | 23.0 | 37 | 25.0 | 1.00 (Ref) |
| Quartile 2 | 46 | 31.1 | 37 | 25.0 | 1.68 (0.74,3.80) |
| Quartile 3 | 46 | 31.1 | 37 | 25.0 | 1.56 (0.68,3.59) |
| Quartile 4 | 22 | 14.9 | 37 | 25.0 | 1.14 (0.44,2.95) |
| Mean | SD | Mean | SD | ||
| EDA:EMC ratio, continuous2 | 2.2 | 0.7 | 2.5 | 1.1 | 0.92 (0.66,1.28) |
| EDA, continuous2,3 | 7.8 | 0.6 | 7.8 | 0.9 | 1.07 (0.72,1.60) |
| EMC, continuous2,3 | 13.4 | 0.5 | 13.3 | 0.6 | 1.27 (0.74,2.16) |
| Among cases with biospecimen ≥2 years prior to diagnosis and matched controls (N=359) | |||||
| EDA ratio | |||||
| Quartile 1 | 41 | 23.0 | 46 | 25.4 | 1.00 (Ref) |
| Quartile 2 | 48 | 27.0 | 45 | 24.9 | 1.60 (0.75,3.41) |
| Quartile 3 | 57 | 32.0 | 44 | 24.3 | 1.84 (0.87,3.90) |
| Quartile 4 | 32 | 18.0 | 46 | 25.4 | 1.45 (0.62,3.37) |
| Mean | SD | Mean | SD | ||
| EDA:EMC ratio, continuous2 | 2.3 | 0.8 | 2.4 | 1.0 | 1.08 (0.80,1.47) |
| EDA, continuous2,3 | 7.8 | 0.7 | 7.8 | 0.8 | 1.22 (0.83,1.78) |
| EMC, continuous2,3 | 13.4 | 0.6 | 13.3 | 0.6 | 1.19 (0.73,1.93) |
1.
Model adjusted for matching factors (randomization center, age, race/ethnicity, hysterectomy status, observational study enrollment), and covariates associated with the outcome: income, estrogen + progestin menopausal hormone therapy use, age at first period, age at menopause, percent body fat, total energy expenditure, dietary fiber, and Calcium + Vitamin D trial assignment
2.
Log-transformed
3.
Model additionally adjusted for creatinine.